SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen
The relative contribution of each pathway to the overall oxidation of tamoxifen is shown by the thickness of the arrow.
Publication
SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. () Ann M Moyer, et al. Pharmacogenomics. ;12(11):1535-1543. Figure: F1.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | OCH,CHN | CHN | ncbigene_synonym | CHN1 | 1123 |
| Homo sapiens | Primates | OCH,CHN | CHN | ncbigene_synonym | NR4A3 | 8013 |
| Homo sapiens | Primates | CYP3A4 | CYP3A4 | ncbigene_symbol | CYP3A4 | 1576 |
| Homo sapiens | Primates | CYP2B6 | CYP2B6 | ncbigene_symbol | CYP2B6 | 1555 |
| Homo sapiens | Primates | CYP2C9 | CYP2C9 | ncbigene_symbol | CYP2C9 | 1559 |
| Homo sapiens | Primates | CYP2D6 | CYP2D6 | ncbigene_symbol | CYP2D6 | 1565 |
| Homo sapiens | Primates | CYP2D6 | CYP2D6 | ncbigene_synonym | CYP2D7 | 1564 |
| Homo sapiens | Primates | CYP2C19 | CYP2C19 | ncbigene_symbol | CYP2C19 | 1557 |
| Homo sapiens | Primates | CYP1A2 | CYP1A2 | ncbigene_symbol | CYP1A2 | 1544 |
| Homo sapiens | Primates | SULT1A1 | SULT1A1 | ncbigene_symbol | SULT1A1 | 6817 |
| Homo sapiens | Primates | OCH,CH,N | OCN | ncbigene_synonym | BGLAP | 632 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| 4-hydroxytamoxifen | NA | mesh:C016601 | ||
| N-desmethyltamoxifen | N-Desmethyltamoxifen | mesh:C028787 | N-desmethyltamoxifen | chebi:80554 |
| 4-hydroxy-N-desmethyltamoxifen | 4-Hydroxy-N-desmethyltamoxifen | mesh:C055492 | 4-hydroxy-N-desmethyltamoxifen | chebi:80555 |
| Endoxifen | 4-Hydroxy-N-desmethyltamoxifen | mesh:C055492 | 4-hydroxy-N-desmethyltamoxifen | chebi:80555 |
| Tamoxifen | Tamoxifen | mesh:D013629 | tamoxifen | chebi:41774 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|